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Abstract
Background: Smoking is known to cause chronic inflammatory changes in the bronchi and to
contribute to airway hyper-reactivity, such as in bronchial asthma. To study the effect of smoking
on the endothelin system in rat airways, bronchial segments were exposed to DMSO-soluble
smoking particles (DSP) from cigarette smoke, to nicotine and to DMSO, respectively.
Methods: Isolated rat bronchial segments were cultured for 24 hours in the presence or absence
of DSP, nicotine or DMSO alone. Contractile responses to sarafotoxin 6c (a selective agonist for
ETB receptors) and endothelin-1 (an ETA and ETB receptor agonist) were studied by use of a
sensitive myograph. Before ET-1 was introduced, the ETB receptors were desensitized by use of
S6c. The remaining contractility observed was considered to be the result of selective activation of
the ETA  receptors. ETA  and ETB  receptor mRNA expression was analyzed using real-time
quantitative PCR. The location and concentration of ETA and ETB receptors were studied by means
of immunohistochemistry together with confocal microscopy after overnight incubation with
selective antibodies.
Results: After being cultured together with DSP for 24 hours the bronchial segments showed an
increased contractility mediated by ETA and ETB receptors, whereas culturing them together with
nicotine did not affect their contractility. The up-regulation of their contractility was blunted by
cycloheximide treatment, a translational inhibitor. No significant change in the expression of ETA
and ETB receptor mRNA through exposure to DMSO or to nicotine exposure alone occurred,
although immunohistochemistry revealed a clear increase in ETA and ETB receptors in the smooth
muscle after incubation in the presence of DSP. Taken as a whole, this is seen as the presence of a
translation mechanism.
Conclusion: The increased contractility of rat bronchi when exposed to DSP appears to be due
to a translation mechanism.
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Background
Globally nearly 5 million deaths per year, as well as 12%
of the deaths of people over 30 years of age are attributa-
ble to smoking, which makes smoking one of the world's
most important health issues [1]. Cigarette smoke is
known not only to cause chronic obstructive pulmonary
disease, cancer, chronic bronchitis and asthma generally
but also to cause suboptimal lung growth during the pre-
adolescent and adolescent years [2]. It is a composite of
irritant molecules, including acetaldehyde, hydroqui-
none, formaldehyde, benzo [a]pyrene, cresol, nicotine,
catechol, acrolein, coumarin, anthracene, nitrogen oxides,
and heavy metals [3]. Cigarette smoke causes rapid cell
proliferation in the small airways and the associated pul-
monary arteries [4].
Endothelin-1(ET-1) is the most potent vasoactive peptide
described to date [5] and appears to have an important
role in the regulation of pulmonary functions. It is synthe-
sized, stored, released and metabolized in the lungs of
many species including rat [6] and man [7], suggesting it
to have a role both in normal physiology and in patho-
physiological processes. The responses to ET-1 are medi-
ated through endothelin type A (ETA) and type B (ETB)
receptors. ET-1 has a similar affinity for ETA and for ETB
receptors. In the tracheal smooth muscle and peripheral
lung tissue of the rat ETA and ETB receptors are found in
approximately equal numbers [8,9], whereas in the
smooth muscle of the human bronchial airway ETB recep-
tors predominate [10]. Both ETA and ETB receptors are
present on smooth muscle cells of the airways, where they
mediate strong contractions, although some ETB receptors
are present on the airway epithelium as well, where they
can induce relaxation through the release of nitric oxide
[11]. ET-1 acts as a co-mitogen together with such factors
as epidermal growth factor [12] It also causes increased
secretion from both mucous and serous cells [13].
BQ-610, a selective ETA  receptor antagonist, blocks
mitogenesis induced in rat airways by cigarette smoke
[14] and pretreatment by Bosentan, a nonselective
endothelin receptor antagonist, inhibits the eosinophilic
inflammatory response to Sephadex in BALF and in lung
tissue [15]. The plasma endothelin level in humans is
increased after smoking [16]. Pro-inflammatory media-
tors such as tumor necrosis factor-α (TNF-α) and inter-
leukin-1β (IL-1β) have been found to promote increased
production of endothelin-1 in guinea-pig cultured tra-
cheal airway epithelial cells [17] and in murine tracheal
segments. IL-1β up regulates the mRNA expression for ET-
1 in mouse airways in which the epithelium is intact [18].
After treatment of human temporal arteries by IL-1β, a
pro-inflammatory cytokine, both maximal contraction
and potency mediated by ETB receptors have been found
to increase [19].
The present study examines functional changes in bron-
chial ET receptors caused by smoking particles and inves-
tigates the underlying mechanisms causing these changes.
Methods
Tissue preparation and organ culture
Male Sprague Dawley rats (body weight 250 g, M&B, Den-
mark) were acclimatized for a week under standardized
temperature (21–22°C), humidity (50–60%) and light
(12:12 light-dark) conditions in the Animal Department
of Wallenberg center in Lund. The rats were killed by CO2
and were exsanguinated. The lungs were immersed in cold
buffer solution (composition, see below) and the bronchi
were freed of adhering lung tissue down to the third gen-
eration (0.5 mm) by dissection under a microscope. Cir-
cular segments were cut from the bronchi with a diameter
of 0.5–1 mm.
The bronchial segments were placed individually in wells
containing DMEM, DMSO-solution (composition, see
below) or nicotine and were put in an incubator for 24
hours. Incubation was carried out at 37°C in humidified
air containing 5% CO2. After incubation the bronchial
segments were divided into three groups for functional
myograph studies, for immunohistochemistry and confo-
cal microscopy, and for real-time quantitative RT-PCR for
mRNA expression – such that each animal contributed
one bronchial segment to each of the three studies carried
out. The protocol was approved by the animal ethics com-
mittee at Lund University (M-120-01).
Functional studies
Each bronchial segment was mounted on two L-shaped
metal prongs. One prong was connected to a force dis-
placement transducer attached to a computer for continu-
ous registration of isometric tension and the other to a
displacement device. The segment was immersed in small
(2.5 ml) temperature-controlled (37°C) tissue baths con-
taining a bicarbonate-based buffer solution (see below).
The solution was equilibrated by 5% CO2 in O2, resulting
in a pH of 7.4. Initially the bronchial segments were
allowed to stabilize for 60 min under a tension of 0.8 mN.
The pretension employed was chosen on the basis of pre-
tension-contraction curves in Ca++ free and Ca++ contain-
ing solution as described earlier [20] and as later modified
for bronchial ring segments [Granström, unpublished].
The contractile ability of each segment was first examined
by exposure to a potassium-rich (60 mM) buffer solution
(for composition, see below), which produced a maxi-
mum contractile effect at this concentration. Maximum
contraction was reached within a few minutes. The potas-
sium solution was washed out then by the buffer solution.
The individual segments were only used for further stud-
ies if two strong (>1 mN) reproducible contractions (var-
iation <10%) could be elicited. The contraction inducedBMC Pulmonary Medicine 2006, 6:6 http://www.biomedcentral.com/1471-2466/6/6
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by the K+-solution (60 mM) was used as a contractility ref-
erence and its maximum was defined as 100%. The epi-
thelium was adjudged to be intact since previous studies
of endothelin receptors had not shown any effect of the
presence or absence of the epithelium [21]. At a point 30
minutes before cumulative concentrations of sarafotoxin
(S6c, a specific ETB receptor agonist) or ET-1 were admin-
istered, 3 µmol of indometacin and 100 µmol of L-NG-
monometylarginin (L-NMMA) were added to block the
modifying effects of epithelial prostaglandin and NO
release [22]. The segments were allowed to stabilize at
each contraction level before a higher concentration of the
agonist was added. When the maximum concentration
and contraction that S6c produced was reached, the con-
tractile response was allowed to fade away during a 1-hour
period. Thereafter the tissue bath solution was exchanged
and new substances were added, including S6c. No con-
traction was observed then, indicating a total desensitiz-
ing of ETB. The subsequent administration of ET-1 in
cumulative concentrations resulted in concentration-
effect curves mediated only by contractions via ETA recep-
tors [18]. The maximal contractile force was tested at the
end of each experiment by use of acetylcholine (10-3 M).
Contractility was tested in fresh bronchial segments and
in control segments incubated together with DMSO, nic-
otine or DSP for 24 hours. To confirm that up-regulation
was caused by the translational mechanism, bronchial
segments were incubated for 24 hours in DSP solution
with and without cycloheximide. Acetylcholine contrac-
tion was used as a reference since carbachol induced con-
tractions appear to be more stable under various
conditions of incubation than KCl contractions are
[23,24].
mRNA quantification
Total RNA isolation and reverse transcription into cDNA
Here the bronchial segments were taken from incubation
wells and any residues of surrounding pulmonary tissue
were carefully dissected away. The segments were then
snap frozen in liquid nitrogen for RNA isolation and tran-
scription was carried out. None of these segments had
been used for functional experiments prior to this prepa-
ration. The segments were homogenized in 1 ml of the
RNApro™solution (Q-BIOgene, CA, USA) by use of a Fast-
Prep® instrument (Q-BIOgene, CA, USA). Total RNA was
extracted following a protocol from the FastRNA® Pro kit
supplier. Reverse transcription of total RNA to cDNA was
carried out using the Gene Amp RT kit (PE Applied Biosys-
tems) in a Perkin-Elmer 2400 PCR machine at 42°C for
30 min.
Quantification of the expression of ET-1, ETA, ETB receptor mRNA 
and ET-1 mRNA
Real-time quantitative RT-PCR was performed here by the
GeneAmp SYBR Green PCR kit (PE Applied Biosystems,
USA) in a Perkin-Elmer real-time PCR machine (Gene-
Amp 5700 sequence detection system). The system auto-
matically monitors the binding of a fluorescent dye to
double-strand DNA by real-time detection of the fluores-
cence present during each cycle of PCR amplification. Spe-
cific primers for rat ET-1, ETA, ETB receptors were designed
as below:
ET-1 forward: 5'-TTTTGAAGACCGCGCTGAG-3'
reverse: 5'-GGTTGCTCTGATCGCCTCTG-3'
ETA receptor forward 5'-GTCGAGAGGTGGCAAAGACC-3'
reverse 5'-ACAGGGCGAAGATGACAACC-3'
ETB receptor forward: 5'-GAT ACG ACA ACT TCC GCT
CCA-3'
reverse: 5'-GTC CAC GAT GAG GAC AAT GAG-3'
The housekeeping gene, Elongation factor-1 (EF-1),
mRNA, which is continuously expressed at a constant
level in the cells, was compared in a pilot study with the
housekeeping gene β-actin by use of real-time PCR (data
not shown). EF-1 was employed as a reference, but both
showed the same degree of constancy in the tests. The rat
EF-1 primers were designed as follows:
EF-1 forward: 5'-GCA AGC CCA TGT GTG TTG AA-3'
reverse: 5'-TGA TGA CAC CCA CAG CAA CTG-3'
The PCR reaction, performed in a 50 µl volume, started at
50°C for 2 min, followed by 95°C for 10 min, then 40
PCR cycles at 95°C for 15 sec and 60°C for 1 min. Disso-
ciation curves were run after the real-time PCR, no non-
specific amplification detected in the present study. Each
of the primers was designed using the Primer Express 2.0
software (PE Applied Biosystems, USA) and was synthe-
sized by GibcoBRL Custom Primers (Life Technologies,
Inc., USA).
The gene IDs in the gene bank accession number were as
follows:
ET-1 gene ID (NM_012548)
ETA gene ID (NM_012550)
ETB gene ID (NM_017333)BMC Pulmonary Medicine 2006, 6:6 http://www.biomedcentral.com/1471-2466/6/6
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ET-1 and S6c contraction after 24 H of DSP or nicotine incubation Figure 1
ET-1 and S6c contraction after 24 H of DSP or nicotine incubation. Bronchial smooth muscle cell responses to the 
concentration-dependent application of sarafotoxin 6c (S6c) or endothelin-1 (ET-1) following incubation for 24 h together with 
DSP (A, C) or nicotine (B,D) as compared with incubation control (DMEM). Mean values with S.E.M. are given. Unpaired t-
tests were used to compare the groups in terms of maximum induced contraction; * P < 0.05.
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EF-1 gene ID (BC072542)
The PCR products of ETA (64 bp), ETB (86 bp) and EF-1
(96 bp) were visualized by agarose gel electrophoresis
Electrophoresis and dissociation curves were used to ver-
ify the specificity of the PCR products.
To evaluate the amount of ETA or ETB receptor mRNA a
sample contained, EF-1 mRNA was assessed in the sample
simultaneously. The cycle threshold values of EF-1 mRNA
were used as a reference to quantify the relative amounts
of ETA or ETB receptor mRNA. The relative amount of
mRNA was calculated for the cycle threshold values of ETA
or ETB receptor mRNA in relation to the cycle threshold
values of EF-1 mRNA in the sample.
Immunohistochemistry
After incubation, the bronchial segments were placed on
Tissue TEK (Gibco) and frozen. Three different samples
were used in each group. The segments were sectioned
into 8 µm thick slices in a cryostat. The primary antibodies
used were rabbit antihuman ETB (IBL, 16207, diluted
1:400), goat anti human ETA (Santa Cruz Biotechnologies,
sc-21194, diluted 1:100) and mouse anti rat smooth mus-
cle actin (Serotec, MCA1905T, diluted 1:100). All dilu-
tions were performed in PBS, using 10% fetal calf serum.
The secondary antibodies employed were donkey anti
mouse Cy™5 conjugated (JacksonImmunoResearch, 715-
175-150, 1:100), donkey anti rabbit Cy™3 conjugated
(JacksonImmunoResearch, 711-165-152, 1:100) and
donkey anti goat Cy™2 conjugate (JacksonImmunoRe-
search, 705-225-003) in PBS. The antibodies were
detected at the appropriate wavelength by confocal micro-
scopy (Zeiss, USA), unspecific background being sub-
tracted. Only secondary antibodies were used as a control.
The absolute fluorescence intensity was measured with
ImageJ [25]
Solutions
(A) Standard buffer solution (mM): NaCl 119, KCl 4.6,
CaCl2 1.5, MgCl2 1.2, NaHCO3 15, NaH2PO4 1.2, and glu-
cose 5.5.
(B) 60 mM K+ buffer solution: as above, but with substitu-
tion of equimolar amounts of NaCl containing KCl.
(C) Dimethyl Sulfoxide (DMSO).
(D) Three cigarettes (0.8 mg nicotine per cigarette) were
"smoked" by a water aspirator, the smoke being directed
through a cotton-wool filter. The smoke particles retained
in the filter were dissolved in 1 ml DMSO. The DMSO-sol-
uble smoke particle (DSP) preparations were analyzed by
gas chromatograph-flame ionisation detection (GC-FID,
Agilent 6890N, USA) on a 0.23 mm × 15 mm × 0.25 m
DB-5MS capillary column (Agilent, USA). The GC-FID
temperatures were programmed to increase by 5°C/min
from 50°C, to 280°C and remain there for 3 min. The
concentration of nicotine in DSP was calculated according
to the standard nicotine peak value and area. After DSP
preparations had been analyzed by gas chromatography,
they were diluted by DMSO to standard nicotine content
(0.11 mg/ml) and were used for the organ culture experi-
ments. Pure nicotine was employed at a concentration of
0.10 mg/ml.
Drugs
Sarafotoxin 6c and endothelin-1 were obtained from Aus-
pep (Parkville, Australia) and L-NMMA, indometacin,
acetylcholine and cycloheximide from Sigma (St. Louis
USA). These agents were dissolved and further diluted in
saline containing 0.1% bovine serum albumin (Bering-
werke, Marburg, Germany) to avoid adhesion of peptides
to the vials.
Analysis
Contractile responses in the segments are expressed as the
percentage of contraction induced by 60 mM K+. The Emax
values refer to the maximum contractile effect of an ago-
nist. The pEC50 value (the negative logarithm of the molar
concentration that produced a half-maximum contrac-
tion) was calculated for the concentration above and
below the midpoint of the concentration-response curve
using a straight-line equation.
Statistics
Students' unpaired t-test was used for the molecular stud-
ies. A p-value of <0.05 was considered as significant.
Results
Contractile responses
In bronchial smooth muscle a significant increase was
obtained (p < 0.05) in the maximum contractile response
to S6c following its incubation together with DSP (Figure
1A) but not with nicotine.
ETA receptor contractility was tested after desensitization
of ETB (see MATERIALS AND METHODS/Functional stud-
ies). The contractions produced by ET-1 that follow have
been found to be mediated by ETA receptors and can be
blocked by a selective ETA antagonist [8]. The contractions
were significantly stronger in DSP treated segments (p <
0.05) but not in segments exposed to nicotine (Figure 1C
and 1D). DMSO at the concentration employed did not
affect contractility (not shown).
Segments, that were maximally contracted by ET-1
through use of the ETA receptors, showed no further con-
traction when acetylcholine (10-3 M) was added.BMC Pulmonary Medicine 2006, 6:6 http://www.biomedcentral.com/1471-2466/6/6
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Adding cycloheximide (10 µg mL-1) to segments incu-
bated with DSP for 24 hours showed a significant reduc-
tion of S6c and to a less extent ET-1 contractility (Figure
2).
mRNA studies
The amount of mRNA for ETA and ETB receptors in the
smooth muscle as well as the ET-1 mRNA were quantified
with the real-time PCR. No significant differences
between the control (DMSO), the DSP- and the nicotine-
treated groups (p > 0.05) (Fig. 3A–C).
Immunohistochemistry and confocal microscopy
Immunohistochemistry revealed no up regulation of the
amount of ETA or ETB receptor protein present in smooth
muscle sections of the bronchi after incubation in the
DMEM medium or in the DMEM medium together with
DMSO as compared with the fresh control group (0
hours). ETA and ETB receptor protein staining revealed an
up-regulation of the amount of protein in the DSP treated
group as compared with the other groups (Fig 4A and 4B).
Image analysis of each of the segments showed no differ-
ence between the groups in the amount of actin staining
(not shown) but, there was a significantly stronger ETA
and ETB receptor protein expression (p < 0.05) (Figure 4B,
4C).
Discussion
This is the first study to show lipid-soluble smoking parti-
cles "DSP" to cause a bronchial hyperresponsiveness to
endothelin-1, a strong airway constrictor, and to S6c, a
specific ETB receptor agent. Since no change in mRNA was
found, except in protein expression, the effect can be con-
sidered to be mediated by an increase of the number
endothelin receptors via translation. Smoking has been
shown in the long run to result in airway distortion and
an increase in airflow resistance, and to lead to the airways
becoming muscularized and fibrotic. Similar changes can
be observed after several decades of asthmatic disease.
More recently, it has been shown that in childhood
asthma such changes occur early.
Previous studies of the endothelin system have led to dif-
fering results. We found bronchial biopsies from patients
with asthma and chronic airway obstruction to show sig-
nificantly higher levels of endothelin ETB receptor mRNA
than of endothelin ETA receptor mRNA [26]. Inflamma-
tion induced in the human temporal by the pro-inflam-
matory cytokine interleukin-1beta (IL-1beta) artery has
been found to result in an increase in maximal contrac-
tion and potency in response to S6c but not to any change
in the ETA/ETB receptor mRNA ratio [19]. The explanation
suggested was that IL- 1beta may further stimulate transla-
tion of the mRNA to active receptors. The hyperreactivity
Translational inhibitor (cycloheximide) effect on DSP led to  changes in ET-1 and S6c contractility Figure 2
Translational inhibitor (cycloheximide) effect on DSP 
led to changes in ET-1 and S6c contractility. Rat bron-
chial segments were incubated for 24 hours in DSP in two 
groups. In the one group a translational inhibitor (cyclohex-
imide, 10 µg mL-1) was added. Two-way  Anova with Bonfer-
roni post test was used to compare contraction at different  
concentrations of agonist. * P < 0.05.
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could also be a function of the length of exposure to the
pro-inflammatory stimuli. Culturing murine tracheal seg-
ments in the presence of IL-1β has been found to attenu-
ate the maximal contraction produced by ETB receptors
and downregulated expressions of the ETB  receptor
mRNA. This was first observed after 2 days of culture,
reduction being maximal at 4 days [18]. Bronchial
smooth muscle from rats exposed to cigarette smoke for
two weeks was found to show hyperreactivity to acetyl-
choline but no depolarization due to high K+ level, this
being explained in terms of increased expression of the
RhoA-protein [27].
Another well-known feature of pulmonary inflammation
is epithelial damage. Early asthmatic inflammation has
been found to cause disruption of the epithelium [28]. In
smoking, the respiratory epithelium is damaged or miss-
A and B; Quantitative image analysis of the bronchi for  receptor protein expression under differing experimental  conditions Figure 4
A and B; Quantitative image analysis of the bronchi for 
receptor protein expression under differing experimental 
conditions. ETA and ETB receptor protein showed a signifi-
cant increase (p < 0.05) in DSP treated as compared with 
fresh bronchi, 24 h and 24 h+DMSO treated bronchi.
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mRNA expression of ETA receptors (A), ETB receptors (B)  and ET-1 in the bronchi Figure 3
mRNA expression of ETA receptors (A), ETB recep-
tors (B) and ET-1 in the bronchi. The mRNA expression 
of ETA and ETB receptors and ET-1 in the bronchi was quanti-
fied by means of real-time PCR. Each data point was derived 
from results for at least 3 segments. No differences in the 
expression level after DSP or nicotine treatment were found 
as compared with controls (DMSO), (p > 0.05).
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ing. In the presence of DSP, arterial endothelium lost its
attachment and functional tests showed reduced dilation
[29]. The clearance of ET-1 in the airways through the ETB
receptors on the epithelial cells is probably impaired,
leading to enhanced access of ET-1 to underlying bron-
chial smooth muscle cells [30]. The production of relaxant
factors such as nitric oxide through ET-1 binding to recep-
tors on the epithelial cells is also compromised [11].
Immunostaining of ETA and ETB receptor protein in bronchi Figure 5
Immunostaining of ETA and ETB receptor protein in bronchi. Figure C. Example of immunostaining of ETA and ETB 
receptor protein after 24 h of culture together with DMSO as compared with 24 h of culture together with DSP.BMC Pulmonary Medicine 2006, 6:6 http://www.biomedcentral.com/1471-2466/6/6
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In the present study, involving use of rat bronchi, we
found the maximal contractile response to ETA and ETB
receptors to be significantly augmented by the presence of
DSP but not by nicotine incubation. In preliminary tests
in rat mesentery artery, the water-soluble part of the
smoking particles was not found to alter ETB receptor
expression (data not shown). The identity and the charac-
teristics of the receptors have been analyzed in detail pre-
viously [10]. Further support for the hypothesis of an
endothelin receptor protein increase was obtained by
immunohistochemistry. This revealed a slight increase in
ETA and a strong and significant increase in ETB receptors
after culturing together with DSP. These up-regulated
receptors were located in the smooth muscle cell layer. We
have shown previously that eosinophilic inflammation
induced in vivo by Sephadex results in ETB receptor up reg-
ulation, both functionally and at the mRNA level [21]. We
did not observe any further change in mRNA expression
for ETA or ETB. However, there have been earlier reports of
a decrease in ETB receptor mRNA expression in mouse air-
ways after long-term treatment by IL-1β [18]. To explain
our own results further, we used confocal microscopy to
indicate whether the amount and the localization of
receptor protein were changed. This revealed an up-regu-
lation of ETA and ETB receptors in the smooth muscle cells.
De novo transcription and translation via protein kinase C
[31] and mitogen-activated protein kinases [32,33] have
been shown to occur after organ culture of arterial seg-
ments.
In vascular studies, cytokines derived from inflammatory
cells during airway inflammation, could lead both to
increase in the level of ET-1 and an up regulation of
endothelin receptors that synergistically enhance the con-
tractility of the smooth muscle of the airways. Use of an
endothelin antagonist is already an established treatment
for pulmonary hypertension[34].
Most ET-1 is secreted abluminally towards the smooth
muscle cells. A small part of ET-1 can be measured in
plasma and smoking leads to raised level of plasma ET-1
[16]. In our study we did not measure any ET-1 level but
the mRNA expression of ET-1 was not altered. Thus, if up-
regulation of ET-1 was present in our study, it must be
explained as due to a translational mechanism, since the
mRNA was unaltered. Raised levels of ET-1 may cause a
raised consumption of ETB receptors, i.e. an increased
turnover, explaining varying results in different studies
In order to test whether nicotine per se could be involved
in this process, it was included in our study. We found no
increase in ETA or ETB receptor expression after nicotine
exposure. This is in agreement with the finding elsewhere
that 24 hours of nicotine incubation of human coronary
artery endothelial cells had no effect on the expression of
ET-1 [35].
Conclusion
Although the mechanisms causing the up-regulation of
ETA and ETBreceptors in airways, through de novo synthe-
sis, are not known, the phenomenon has been studied in
detail for blood vessels. Putatively, a regulatory mecha-
nism similar to that in blood vessels could conceivably
take place in bronchi but further study would be needed
to determine this. Other mechanisms for the regulation of
ET-receptors in airway inflammation may hypothetically
occur via such cytokines as tumor necrosis factor-α and
interleukin-1α. Our group has demonstrated that such a
phenomenon can occur in vascular smooth muscle cells
[36,37]. Study of such regulatory mechanisms in the air-
ways can be regarded as extremely important.
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Table 1: Maximal contractile responses after DSP or nicotine 
incubation. The maximal contractile responses (% of maximal 
contraction to 60 mM potassium) and pEC50 of endothelin-1 and 
sarafotoxin 6c in bronchial segments from 24 hour DSP or 
nicotine incubation as compared with control segments The 
values are given as means ± S.E.M., n = 6–10. Unpaired t-tests 
were used to compare the groups in terms of maximum induced 
contraction; #* P < 0.05.
Rat Bronchi
Maximal contraction pEC50
Endothelin-1
Control 121.21 ± 4.84# 7.69 ± 0.49
DSP 154.24 ± 14.88# 7.43 ± 0.35
Nicotine 106.49 ± 7.53 7.39 ± 0.13
Sarafotoxin6c
Control 144.25 ± 4,01* 8.24 ± 0.08
DSP 213.39 ± 20.03* 8.21 ± 0.17
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